Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Oct 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2018 Planned number of patients changed from 104 to 98.
- 11 Jul 2018 Planned number of patients changed from 98 to 104.
- 05 Jun 2018 Enrollment to phase I was started on 29 January 2018 and to date 1 patient has been enrolled as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology